Author: Cecylia S. Lupala; Xuanxuan Li; Jian Lei; Hong Chen; Jianxun Qi; Haiguang Liu; Xiao-dong Su
Title: Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein Document date: 2020_3_27
ID: kifqgskc_9
Snippet: Based on the analysis of the predicted model, sequence alignment, and literature survey, two other systems containing mutations in the human ACE2 were prepared and subject to MD simulation studies. The mutant construct is based on the fact that Rat ACE2 markedly diminishes interactions with SARS spike protein 12 , and it was proposed that the rat ACE2 likely has reduced binding affinity to the CoV2-RBD 13 . To investigate the roles of critical re.....
Document: Based on the analysis of the predicted model, sequence alignment, and literature survey, two other systems containing mutations in the human ACE2 were prepared and subject to MD simulation studies. The mutant construct is based on the fact that Rat ACE2 markedly diminishes interactions with SARS spike protein 12 , and it was proposed that the rat ACE2 likely has reduced binding affinity to the CoV2-RBD 13 . To investigate the roles of critical residues on the ACE2, we created two mutants of the human ACE2 (see Table 1 ): (1) mutant mut_h1, with the ACE2 N-terminal (residue 19-40) mutated to the residues of rat ACE2; and (2) mutant K353H, in which the highly conserved K353 was mutated to histidine (the corresponding amino acid in rat and mouse ACE2 proteins). To focus on the impact of these two binding sites, the rest of the ACE2 were kept to be the same as human ACE2.
Search related documents:
Co phrase search for related documents- amino acid and bind site: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- amino acid and critical residue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- amino acid and MD simulation study: 1, 2, 3, 4
- amino acid and mouse rat: 1, 2, 3, 4, 5, 6, 7, 8, 9
- amino acid and mutant construct: 1, 2, 3
- amino acid and predict model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- amino acid and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- amino acid and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- amino acid and sequence alignment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- amino acid and simulation study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- bind affinity and mouse rat: 1
- bind affinity and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- bind affinity and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- bind affinity and sequence alignment: 1, 2
- bind affinity and simulation study: 1
- bind site and MD simulation study: 1
- bind site and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- bind site and SARS spike protein: 1, 2, 3, 4, 5, 6, 7, 8
- bind site and simulation study: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date